CliffBio
biologic

VPRIV

velaglucerase alfa

Loss of exclusivityFebruary 2022projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameVPRIV
Active ingredientvelaglucerase alfa
Strength400UNITS
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2010
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

VPRIV patent cliff — loss of exclusivity February 2022 | CliffBio